Literature DB >> 29549515

Multidrug-resistant bacterial microorganisms (MDRO) in end-of-life care: development of recommendations for hospitalized patients using a mixed-methods approach.

Maria Heckel1, Stephanie Stiel2, Franziska A Herbst2, Johanna M Tiedtke3, Alexander Sturm4, Thomas Adelhardt5, Christian Bogdan6, Cornel Sieber4, Oliver Schöffski5, Frieder R Lang3, Christoph Ostgathe7.   

Abstract

PURPOSE: Palliative care professionals are frequently confronted with patients colonized or infected with MDRO. One major challenge is how to balance necessary isolation measures and social inclusion as one of the main principles of palliative and end-of-life care. To date, MDRO-specific policies and protocols vary widely between institutions. AIM: provide empirical recommendations on how to deal with hospitalized MDRO patients in end-of-life care.
METHODS: Recommendations were developed based on (i) initial results of face-to-face interviews and focus groups, (ii) impartial experts' comments and consensus on the draft via online survey and (iii) a face-to-face meeting with consortium members to finalize recommendations. Findings of 158 interviews and six focus groups (39 participants) with patients, family caregivers, staff members and institutional stakeholders contributed to the recommendations. The assessments of 17 experts were considered.
RESULTS: In total, 21 recommendations were approved. The recommended strategy in dealing with MDRO at the end of life allows case-based application of protection and isolation measures. MDRO diagnostics and therapy involve screening at admission. The recommendations suggest consideration of required accommodation facilities, provided material as well as staff and time resources. The recommendations further highlight the importance of providing for strategies enabling the patient's social inclusion and provision of verbal and written information about MDRO for patients and family caregivers, transparent medical documentation, and staff member training.
CONCLUSION: The recommendations summarize the perspectives of individuals and groups affected by MDRO at the end of life and provide practical guidance for clinical routine. Further dissemination and implementation requirements are discussed and should contain the evaluation of the knowledge, views, worries, and anxieties of the target groups.

Entities:  

Keywords:  Drug resistance; Empirical research; Methicillin-resistant Staphylococcus aureus; Multiple; Palliative care; Practice guideline; Terminal care

Mesh:

Year:  2018        PMID: 29549515     DOI: 10.1007/s00520-018-4149-6

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  20 in total

1.  [Hygiene measures for infection or colonization with multidrug-resistant gram-negative bacilli. Commission recommendation for hospital hygiene and infection prevention (KRINKO) at the Robert Koch Institute (RKI)].

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2012-10       Impact factor: 1.513

2.  Effects of isolation on patients and staff.

Authors:  Carmen Lupión-Mendoza; María J Antúnez-Domínguez; Carmen González-Fernández; Concepción Romero-Brioso; Jesús Rodriguez-Bano
Journal:  Am J Infect Control       Date:  2015-02-24       Impact factor: 2.918

3.  Psychological effects of source isolation nursing (2): Patient satisfaction.

Authors:  J Rees; H R Davies; C Birchall; J Price
Journal:  Nurs Stand       Date:  2000 Apr 5-11

4.  [Recommendations for prevention and control of methicillin-resistant staphylococcus aureus (MRSA) in medical and nursing facilities].

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2014-06       Impact factor: 1.513

5.  Effects of Methicillin-Resistant Staphylococcus aureus/Multiresistant Gram-Negative Bacteria Colonization or Infection and Isolation Measures in End of Life on Family Caregivers: Results of a Qualitative Study.

Authors:  Maria Heckel; Alexander Sturm; Franziska A Herbst; Christoph Ostgathe; Stephanie Stiel
Journal:  J Palliat Med       Date:  2016-11-18       Impact factor: 2.947

6.  Methicillin-resistant Staphylococcus aureus (MRSA) management in palliative care units and hospices in Germany: a nationwide survey on patient isolation policies and quality of life.

Authors:  Johannes Bükki; Jennifer Klein; Ludmilla But; Thomas Montag; Hans Martin Wenchel; Raymond Voltz; Christoph Ostgathe
Journal:  Palliat Med       Date:  2011-11-01       Impact factor: 4.762

7.  Patients' experiences of being infected with MRSA at a hospital and subsequently source isolated.

Authors:  Eva Skyman; Harrieth Thunberg Sjöström; Lisbeth Hellström
Journal:  Scand J Caring Sci       Date:  2010-01-11

8.  ["I cannot kiss my wife"- An Analysis of Daily Experiences of MRSA-carriers].

Authors:  H Raupach-Rosin; C J Klett-Tammen; O Schmalz; A Karch; S Castell; R Mikolajczyk
Journal:  Gesundheitswesen       Date:  2015-11-09

9.  The use of Grounded theory in palliative care: methodological challenges and strategies.

Authors:  Stephanie Stiel; Martina Pestinger; Albine Moser; Guy Widdershoven; Ulrich Lüke; Guido Meyer; Raymond Voltz; Friedemann Nauck; Lukas Radbruch
Journal:  J Palliat Med       Date:  2010-08       Impact factor: 2.947

10.  The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines.

Authors:  Melissa C Brouwers; Kate Kerkvliet; Karen Spithoff
Journal:  BMJ       Date:  2016-03-08
View more
  2 in total

1.  Addressing multidrug resistant pathogens in pediatric palliative care patients-the nurses point of view: A qualitative study.

Authors:  Pia Schmidt; Almut Hartenstein-Pinter; Julia Wager; Carola Hasan; Boris Zernikow
Journal:  Palliat Med       Date:  2019-10-29       Impact factor: 4.762

2.  Interprofessional perceptions of emotional, social, and ethical effects of multidrug-resistant organisms: A qualitative study.

Authors:  Stefan Bushuven; Markus Dettenkofer; Andreas Dietz; Stefanie Bushuven; Petra Dierenbach; Julia Inthorn; Matthias Beiner; Thorsten Langer
Journal:  PLoS One       Date:  2021-02-22       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.